FX Solutions Receives FDA 510k Clearances for Glenoid Baseplate With a Central Screw and 32mm Glenosphere and Humeral Cups

Further Expands FX's Shoulder Arthroplasty Portfolio

The Glenoid Baseplate includes a Central Screw that has (7) different central screw size length options ranging from 8mm to 20mm in 2mm increments. This provides an alternative to the glenoid baseplate having a central post and post extensions that FX currently has available to the US market.

FX Solutions notes the addition of the glenoid baseplate with a central screw allows surgeons perioperative options to address a variety of deficiencies and can now accommodate an even larger patient population and surgeon’s needs.

The 32mm Glenosphere and Humeral Cups further expand the offerings that FX has available to the US market, which includes the existing sizes of 36mm and 40mm. With the 32mm components added to the FX portfolio, surgeons may be able to address more diverse patient needs.

“These are significant achievements and additions for our portfolio. There is a constant need and request for exactly these types of implants. They complement what we already have and, even more so, allows us to further compete in an extremely competitive market,” said Baptiste Martin, CEO of FX Shoulder USA. “These additions continue our adventure…” he continued to say.

To see the entire FX portfolio, you can visit their exhibit booth at AAOS in Orlando from March 25-27, 2020.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”